Jeena Sikho Lifecare Limited, a prominent player in the Ayurvedic healthcare sector, has made significant strides in advancing evidence-based Ayurvedic practices with the publication of four pioneering case studies. The research, co-authored by the company's Managing Director Acharya Manish Grover and other medical professionals associated with the firm, focuses on innovative Ayurvedic approaches to liver health, tubal blockage, early-stage Type 2 diabetes, and liver disease management.

Groundbreaking Research in Ayurvedic Medicine

The case studies, which demonstrate the potential of Ayurvedic treatments in addressing complex health issues, include:

1. Restoration of liver health in hepatomegaly with fatty liver
2. Management of tubal blockage
3. Treatment of early-stage Type 2 diabetes mellitus
4. Liver disease management through diet and Panchakarma therapy

These studies showcase the efficacy of Ayurvedic interventions in conditions that are increasingly prevalent in modern society.

Collaborative Effort in Ayurvedic Research

The research team, led by Acharya Manish Grover, included several medical professionals associated with Jeena Sikho Lifecare Limited:

• Dr. Gitika Chaudhary
• Dr. Richa
• Mr. Upam
• Dr. Tanu Rani
• Dr. Shweta
• Dr. Navneet Kaur
• Mr. Siddharth Charan

This collaborative approach underscores the company's commitment to fostering a team of experts dedicated to advancing Ayurvedic science.

Implications for Ayurvedic Practice

The case studies reported positive outcomes across various health conditions:

• Normalized liver function tests in hepatomegaly cases
• Restored tubal patency in fertility-related issues
• Improved markers in early-stage diabetes management
• Effective liver disease management through dietary and therapeutic interventions

These results highlight the potential of Ayurvedic treatments as complementary or alternative approaches to conventional medicine, particularly in chronic and lifestyle-related disorders.

Commitment to Evidence-Based Ayurveda

Acharya Manish Grover, Managing Director of Jeena Sikho Lifecare Limited, emphasized the importance of this research: "These case studies represent our ongoing commitment to advancing Ayurvedic research and promoting evidence-based clinical practices. By documenting and sharing these findings, we aim to contribute to the growing body of scientific literature supporting Ayurvedic interventions."

The publication of these case studies marks a significant step in bridging traditional Ayurvedic knowledge with modern scientific methodology. It also reinforces Jeena Sikho Lifecare Limited's position as a leader in innovative Ayurvedic research and treatment.

As the healthcare community continues to seek integrative approaches to complex health issues, research like this from Jeena Sikho Lifecare Limited paves the way for a more comprehensive understanding of Ayurveda's role in modern medicine. The company's efforts in documenting and sharing these clinical experiences contribute significantly to the field, potentially influencing future research directions and treatment protocols in Ayurvedic medicine.

Jeena Sikho Lifecare Limited (JSLL) has announced a series of significant changes in its leadership and employee benefits structure, as approved by its Board of Directors on August 27, 2025.

New Chief Operating Officer

The company has appointed Sahil Jain as its new Chief Operating Officer (COO), effective August 27, 2025. Jain brings over eight years of experience within JSLL, having previously led key departments including IT, Marketing, Call Center Operations, and Administration. His background also includes valuable experience at global technology firms IBM and HCL Australia.

Employee Stock Option Scheme 2025

JSLL's Board has approved an Employee Stock Option Scheme (ESOP) 2025, subject to shareholder approval. The scheme will cover up to 250,000 stock options at an exercise price of Rs. 2.00 per share. This initiative aims to benefit eligible employees and directors of the company and its group companies.

Board Changes

In a significant board restructuring, Shreya Grover has been redesignated from Non-Executive Director to Whole-Time Director for a five-year term, effective August 27, 2025. Grover, who is the daughter of Managing Director Manish Grover, has been associated with the company since June 2021. Her new role will focus on guiding the company's growth strategies, including the expansion of Ayurveda hospitals and the launch of OTC Ayurveda products.

Other Key Decisions

The Board made several other important decisions:

• Appointment of Ankur Singh & Associates as Secretarial Auditor for a five-year term from FY 2025-26 to FY 2029-30.
• Scheduling of the 8th Annual General Meeting (AGM) for September 29, 2025.
• Recommendation of a final dividend of Rs. 1.10 per equity share for the financial year ended March 31, 2025, subject to shareholder approval.

Financial Implications

The proposed ESOP scheme and dividend payout indicate the company's focus on employee retention and shareholder value. However, the financial impact of these decisions will be clearer in the coming quarters.

These developments suggest that Jeena Sikho Lifecare is positioning itself for growth and expansion in the Ayurveda and wellness sector, with a renewed focus on operational efficiency and strategic leadership.